Sec. 723. Treatments for acute radiation syndrome incurred by overseas personnel: procurement; pre-positioning
201 words·~1 min read·
/bill/118/hr/8070/rds/section-723A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall establish requirements for the procurement and pre-positioning of treatments for acute radiation syndrome and thermal burns incurred by members of the Armed Forces assigned to duty locations outside the United States. In establishing such requirements, the Secretary shall take into account— the number of such members deployed in or near conflict zones wherein the use of nuclear weapons is a threat; and peer-reviewed and published scientific studies regarding the efficacy and operational requirements of such treatments.
Not later than September 30, 2025, the Secretary shall submit to the Committees on Armed Services of the Senate and House of Representatives a briefing regarding the requirements established under subsection (a). In this section: The term biological product has the meaning given such term in section 319F–1 of the Public Health Service Act (42 U.S.C. 247d-6a). The term device and drug have the meaning given such terms in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).
The term treatment means a biological product, device, or drug approved, licensed, cleared, or otherwise authorized by the Food and Drug Administration.
Connectionstraces to 2
Citation graph
cites case law
Sec. 723
Treatments for acute radiation syndrome incurred by overseas personnel: procurement; pre-positioning
Cites 2Cited by 0 across 0 sources